Lisofylline as a modifier of radiation therapy

Oncology Research

Volumn 8, Issue 12, 1996, Pages 513-518

  Wong, Julia S ^a   Ara, Gulshan ^a   Keyes, Susan R ^a   Herbst, Roy ^a   Coleman, C Norman ^a   Teicher, Beverly A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

lisofylline; pentoxifylline; radiation sensitization

Indexed keywords

LISOFYLLINE; METHYLXANTHINE DERIVATIVE; PENTOXIFYLLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL HYPOXIA; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GAMMA RADIATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE;

EID: 0030441833     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. 1. Busse, P. M.; Bose, S. K.; Jones, R. W.; Tolmach, L. J. The action of caffeine on X-irradiated HeLa cells: II. Synergistic lethality. Radiat. Res. 71:666-677; 1977.
2. 2. Evenson, D. P.; Baer, R. K.; Jost, L. K.; Gesch, R. W. Toxicity of thiotepa on mouse spermatogenesis as determined by dual-parameter flow cytometry. Toxicol. Appl. Pharmacol. 82:151-163; 1986.
3. 2 arrest. Radiat. Res. 76:292-307; 1978.
4. 4. Fingert, H. J.; Chang, J. D.; Pardee, A. B. Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Cancer Res. 46:2463-2467; 1986.
5. 5. Fingert, H. J.; Pu, A. T.; Chen, Z.; Googe, P. B.; Alley, M. C.; Pardee, A. B. In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa. Int. J. Radiat. Oncol. Biol. Phys. 17: 101-107; 1988.
6. 6. Fraval, H. N. A.; Roberts, J. J. Effects of cis-platinum(II) diamine dichloride on survival and the rate of DNA synthesis in synchronously growing Chinese hamster V79-379A cells in the absence and presence of caffeine inhibited post replication repair: evidence for an inducible repair mechanism. Chem. Biol. Interact. 23:99-110; 1978.
7. 7. Fraval, H. N. A.; Roberts, J. J. Effects of cis-platinum(II) diamine dichloride on survival and the rate of DNA synthesis in synchronously growing HeLa cells in the absence and presence of caffeine. Chem. Biol. Interact. 23:111-119; 1978.
8. 2 on the frequency of chromosomal aberrations induced by thiotepa, mitomycin C and N-methyl-N-nitro-N′-nitrosoguanidine in human lymphocytes. Mutat. Res. 126:251-258; 1984.
9. 9. Kihlman, B. A.; Anderson, H. C. Synergistic enhancement of the frequency of chromatid aberrations in cultured human lymphocytes by combinations of inhibitors of DNA repair. Mutat. Res. 150:313-325; 1985.
10. 10. Lau, C. C.; Pardee, A. B. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc. Nat. Acad. Sci. USA 79:2942-2946; 1982.
11. 11. Tolmach, L. J.; Busse, P. M. The action of caffeine on x-irradiated HeLa cells. IV. Progression delays and enhanced cell killing at high caffeine concentrations. Radiat. Res. 82:374-392; 1980.
12. 12. Tolmach, L. J.; Duncan, P. G.; Beetham, K. L. The action of caffeine on x-irradiated HeLa cells. IX. Hypothermic effects. Radiat. Res. 122:280-287; 1990.
13. 13. Waldren, C. A.; Rasko, I. Caffeine enhancement of x-ray killing in cultured human and rodent cells. Radiat. Res. 73:95-110; 1978.
14. 14. Horsman, M. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. Acta Oncologica 34:571-587; 1995.
15. 15. Teicher, B. A. Physiologic mechanisms of therapeutic resistance: blood flow and hypoxia. In: Fisher G. ed. Hematology/Oncology Clinics of North America, Drug Resistance in Clinical Oncology and Hematology. Philadelphia: W. B. Saunders Co.; 1995:pp. 475-506.
16. 16. Teicher, B.; Alvarez, S. Chemical radiation sensitizers and protectors. In: Foye, W., ed. Cancer chemotherapeutic agents. Washington, DC: American Chemical Society; 1995:pp. 501-527.
17. 17. Teicher, B. A.; Holden, S. A.; Herman, T. S.; Epelbaum, R.; Pardee, A. B.; Dezube, B. Effect of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo. Anticancer Res. 11:153-158; 1991.
18. 18. Teicher, B. A.; Herman, T. S.; Tanaka, J.; Dezube, B.; Pardee, A.; Frei, E., III. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma. Cancer Chemother. Pharmacol. 28:45-50; 1991.
19. 19. Tanaka, J.; Teicher, B. A.; Herman, T. S.; Holden, S. A.; Dezube, B.; Frei, E., III. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo. Int. J. Cancer 48:631-637; 1991.
20. 20. Teicher, B. A.; Alvarez, S.; Sotomayor, E. A.; Robinson, M. F.; Dupuis, N. P.; Schwartz, G. N.; Frei, III, E. Tumor oxygenation and radiosensitization by pentoxifylline and a perflubron emulsion/carbogen breathing. Int. J. Oncol. 2:13-21; 1993.
21. 21. Stelzer, K.; Koh, W.; Peterson, L.; Griffin, T. Effect of high dose pentoxifylline on acute radiation-induced lung toxicity in a rat lung perfusion model. Int. J. Radiat. Oncol. Biol. Phys. 34:111-15; 1996.
22. 22. Bessler, H.; Gilgal, R.; Diadetti, M.; Zahavi, I. Effect of pentoxifylline on the phagocytic activity, cAMP levels and Superoxide anion production by monocytes and polymorphonuclear cells. J. Leuk. Biol. 40:747-754; 1986.
23. 23. Schror, R. H. Antithrombotic potential of pentoxifylline -a hemorheologically active drug. Angiology 36: 387-398; 1985.
24. 24. Dezube, B. J.; Fridovich-Keil, J. L.; Bouvard, I.; Lange, R. F.; Pardee, A. B. Pentoxifylline and well being in patients with cancer. Lancet 335:662; 1990.
25. 25. Strieter, R. M.; Remick, D. G.; Ward, P. A.; Spengler, R. N.; Lynch, J. P., III; Kunkel, S. L. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem. Biophys. Res. Commun. 155:1230-1236; 1988.
26. 26. Singer, J. W.; Bursten, S. L.; Rice, G. C.; Gordon, W. P.; Bianco, J. A. Inhibitors of intracellular phosphatidic acid production: novel therapeutics with broad clinical applications. Exp. Opin. Invest. Drugs 3:631-643; 1994.
27. 27. Bursten, S.; Weeks, R.; West, J.; Le, T.; Wilson, T.; Porubek, D.; Bianco, J. A.; Singer, J. W.; Rice, G. C. Potential role for phosphatidic acid in mediating the inflammatory responses to TNFα and IL-1β;. Circulatory Shock 44:14-29; 1994.
28. 28. Rice, G. C.; Brown, P. A.; Nelson, R. J.; Bianco, J. A.; Singer, J. W.; Bursten, S. Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc. Nat. Acad. Sci. USA 91:3857-3861; 1994.
29. 29. Abraham, E.; Bursten, S.; Shenkar, R.; Allbee, J.; Tuder, R.; Woodson, P.; Guidot, D. M.; Rice, G.; Singer, J. W.; Repine, J. E. Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice. J. Exp. Med. 181:569-575; 1995.
30. 30. Clarke, E.; Rice, G. C.; Weeks, R. S.; Jenkins, N.; Nelson, R.; Bianco, J. A.; Singer, J. W. Lisofylline inhibits transforming growth factor β; release and enhances trilineage hematopoietic recovery after 5-fluorouracil treatment in mice. Cancer Res. 56:105-112; 1996.
31. 31. Singer, J.; List, A.; Federighi, D.; Michnick, T.; Bursten, S. Serum hydroperoxy and hydroxyoctadecadienoic acids (HPODE and HODE) increase in response to total body irradiation (TBI) and are suppressed by lisofylline (LSF) in allogeneic BMT patients. Blood 88 suppl 1:458a; 1996.
32. 32. Rice, G.; Rosen, J.; Weeks, R.; Michnick, J.; Bianco, J.; Singer, J. CT1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo. Shock 1:254-66; 1994.
33. 33. Rockwell, S. Cytotoxic and radiosensitizing effects of hypoxic cell sensitizers on EMT-6 mouse mammary tumor cells in vivo and in vitro. Br. J. Cancer 37: 212-215; 1978.
34. 34. Sotomayor, E. A.; Teicher, B. A.; Schwartz, G. N.; Holden, S. A.; Menon, K.; Herman, T. S.; Frei, E., III. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo. Cancer Chemother. Pharmacol. 30:377-384; 1992.
35. 35. Rockwell, S. C.; Kallman, R. F.; Fajardo, L. F. Characteristics of serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J. Natl. Cancer Inst. 49:735-747; 1972.
36. 36. Teicher, B. A.; Lazo, J. S.; Sartorelli, A. C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res. 41:73-81; 1981.
37. 37. Teicher, B. A.; Rockwell, S.; Lee, J. B. Radiosensitivity by nitroaromatic Pt(II) complexes. Int. J. Radiat. Oncol. Biol. Phys. 11:937-940; 1985.
38. 38. Teicher, B. A.; Herman, T. S.; Holden, S. A.; Wang, Y.; Pfeffer, M. R.; Crawford, J. M.; Frei, E., III. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247:1457-1461; 1990.
39. 39. Teicher, B. A.; Rose, C. M. Perfluorochemical emulsions can increase tumor radiosensitivity. Science 223: 934-936; 1984.
40. 40. Teicher, B. A.; Holden, S. A.; Jacobs, J. L. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res. 47:513-518; 1987.
41. 41. Hall, E. J. Radiobiology for the Radiobiologist (2nd ed.) Philadelphia: Harper & Row; 1978:pp. 235-243.
42. 42. Hall, E. Radiation dose rate: a factor of importance in radiobiology and radiotherapy. Brit. J. Radiol. 45:81-97; 1972.
43. 43. Fu, K.; Phillips, T.; Lawrence, J.; Smith, V. Tumor and normal tissue response to irradiation in vivo: variation with decreasing dose rates. Radiol. 114:709-716; 1975.
44. 44. Steel, G.; Down, J.; Peacock, J.; Stephens, T. Dose-rate effects and the repair of radiation damage. Radiother. Oncol. 5: 321-31; 1986.